"Klinische Studien sind der Schlüssel zu neuen Erkenntnissen in der Diagnostik und Therapie von Erkrankungen. Wir sind stolz, in der Schweiz dazu beizutragen."

Klaudia Georgi, Director Clinical Research MSD Switzerland & Austria

15

In der Schweiz zugelassene First-in-Class-Medikamente seit 2000

(Stand: 05/2021)

35

Anzahl klinische Studien in der Schweiz

(Stand: 05/2021)

95

Millionen Schweizer Franken in die Forschung investiert, seit 2012

(Stand: 05/2021)

Die klinische Forschung von MSD Schweiz wird in unserer Niederlassung im Citybay in Luzern koordiniert.
Unsere Niederlassungen

Das klinische Studienprogramm von MSD in der Schweiz (Stand: 05/2021)

Laufende klinische Studien von MSD in der Schweiz (Stand: 05/2021)

(veröffentlicht auf www.clinicaltrials.gov)

Laufende klinische Studien von MSD in der Schweiz im Bereich Infektiologie (Stand 05/2021)

Studie

Durchführungsort

HIV

MK-8591A-017 - recruitment closed
A Phase 3 Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to MK-8591A Once-Daily in Participants With HIV-1 Virologically Suppressed on Antiretroviral Therapy

Basel, Bern, Genf, Lugano, St. Gallen, Zürich

MK-8591-013 - still recruiting
A Phase 2b, Randomized, Active-Controlled, Double-Blind, Dose-Ranging Clinical Study to Evaluate a Switch to Islatravir (ISL) and MK-8507 Once-Weekly in Adults with HIV-1 Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) Once Daily

Basel, Bern, Genf, Lausanne, Zürich

MMK-8591A-033 - study in start up
A Phase 3 Open-label Rollover Clinical Study of Doravirine/Islatravir (DOR/ISL) Once-daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL in a Phase 2 or Phase 3 DOR/ISL Clinical Study

Basel, Bern, Genf, Lugano, St.Gallen, Zürich

Laufende klinische Studien von MSD in der Schweiz im Bereich Onkologie (Stand 05/2021)

Studie

Durchführungsort

Blasenkrebs

MK-3475-676/KEYNOTE-676 - still recruiting
A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HRNMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)

Basel, Genf, Zürich

Blutkrebs (Hämatologische Malignome)

MK-1026-003 - study in start up
A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies

Bellinzona, Bern, Zürich

Darmkrebs (Kolorektales Karzinom)

MK-3475-177/KEYNOTE-177 - recruitment closed
A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma

Genf, Zürich

Hautkrebs (Melanom - schwarzer Hautkrebs)

MK-3475-U02A - still recruiting
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02) - refractory

Lausanne, Zürich

MK-3475-U02B - still recruiting
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02) - 1st line

Lausanne, Zürich

MK-3475-U02C - still recruiting
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02) - neoadjuvant

Lausanne, Zürich

MK-3475-U02D - still recruiting
A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02) - neoadjuvant

Lausanne, Zürich

MK-3475-054 / KEYNOTE-054 - outsourced
Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group

Genf, St. Gallen, Zürich

MK-3475-716/KEYNOTE-716 - recruitment closed
Adjuvant Therapy with Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study

Bellinzona, Basel, Bern, Chur, Genf, Lausanne, Sion, St. Gallen, Zürich

MK-7902-003 - still recruiting
A Phase III, Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) and Lenvatinib (E7080/MK-7902) Versus Pembrolizumab Alone as First-line Intervention in Participants with Advanced Melanoma (LEAP-003)

Basel, Chur, Zürich

Kopf-und Halskrebs

MK-3475-040/KEYNOTE-040 - will be closed shortly
A Phase III Randomized Trial of MK-3475 (Pembrolizumab) versus Standard Treatment in Subjects with Recurrent or Metastatic Head and Neck Cancer

Genf, Luzern

MK-3475-048/KEYNOTE-048 - will be closed shortly
A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Zürich, Lausanne

MK-3475-689/KEYNOTE-689 - still recruiting
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

Bellinzona, Genf, Zürich

Leberkrebs

MK-3475-937/KEYNOTE-937 - still recruiting
A phase III adjuvant, randomized, placebo – controlled, double-blinded study, in surgically resected or ablated HCC patients

Basel, Bern, Genf, Lausanne, St.Gallen, Zürich

Leberzellkrebs (Hepatozelluläres Karzinom)

MK-1308A-004 - still recruiting
A Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK 1308A (Coformulated MK 1308/MK 3475) in Combination with Lenvatinib (E7080/MK 7902) in First-line Therapy of Participants with Advanced Hepatocellular

Bern, Genf, Lausanne, Zürich

Lungenkrebs

MK-3475-042/KEYNOTE-042 - will be closed shortly
A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) Versus Platinum Based Chemotherapy in Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer

Basel, Bern

MK-3475-091/KEYNOTE-091 - outsourced
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)

Basel, Bellinzona, Bern, Chur, Genf, Lausanne, Luzern, St. Gallen, Winterthur, Zürich

MK-3475-495/KEYNOTE-495; KeyImPaCT - still recruiting
KeyImPaCT: A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer

Basel, Chur, Genf, St. Gallen, Zürich

MK-3475-604/KEYNOTE-604 - recruitment closed
A Phase 3 Randomized, Double-Blind, Placebo-controlled Trial of Pembrolizumab (MK-3475/SCH900475) in Combination with Etoposide/Platinum (Cisplatin or Carboplatin) for the First-line Treatment of Subjects with Extensive Stage Small Cell Lung Cancer

Chur, Lausanne

MK-3475-867/KEYNOTE-867 - still recruiting
A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC)

Genf, Zürich

MK-3475-B98 - study in start up
A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination with Investigational Agents for the Treatment of Participants With PD-1/L1-refactory Extensive Stage Small Cell Lung Cancer in Need of Second-Line Therapy

Lausanne, St.Gallen

MK-3475-B99 - study in start up
A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First Line Treatment of Participants with Extensive Stage Small Cell Lung Cancer

Lausanne, St.Gallen

MK-7684A-002 - study in start up
A Phase 2, Multicenter, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-small Cell Lung Cancer With Progressive Disease After Treatment With a Platinum Doublet Chemotherapy and Immunotherapy

Bellinzona, Lausanne

Magenkrebs

MK-3475-062/KEYNOTE-062 - will be closed shortly
A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin+5-Fluorouracil Versus Placebo+Cisplatin+5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Chur

MK-3475-859/KEYNOTE-859 - recruitment closed
A Phase III, randomized, double-blind clinical study of pembrolizumab (MK 3475) plus chemotherapy versus placebo plus chemotherapy as first line treatment in participants with previously untreated, HER2 negative, advanced gastric or gastroesophageal junction adenocarcinoma

Basel, Bellinzona, Chur, Luzern, Zürich

Nierenkrebs (Nierenzellkarzinom)

MK-6482-011 – still recruiting
An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy

Bellinzona, Chur, Genf, Lausanne, Zürich

Prostatakrebs

MK-3475-199/KEYNOTE-199 - recruitment closed
Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Basel, Chur, Luzern, St. Gallen

MK-3475-991 / Keynote 991 - still recruiting
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)

Chur, Lausanne, St. Gallen, Zürich

Solide Tumore

MK-7902- 005 - still recruiting
A Multicenter, Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005)

Bellinzona, Bern, Chur, Genf, St. Gallen, Zürich

MK-3475-587/KEYNOTE-587 - still recruiting
Long-term Safety and Efficacy Extension Study for Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study

Basel, Zürich

MK-7339-002 - still recruiting
A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer

Bellinzona, Genf, Zürich

MK-8353-014 - will be closed shortly
Phase 1 b Open-label Study of MK-8353 in Combination with Selumetinib (MK-5618) in Participants with Advanced/Metastatic Solid Tumors

Bellinzona

Zur Übersicht der schweizweiten Studien, die Teilnehmende suchen. www.kofam.ch

Wir möchten Menschen mit Krebs Hoffnung schenken

Wir investieren in die Entwicklung innovativer onkologischer Medikamente, um Menschen mit Krebserkrankungen zu helfen.

Mehr erfahren

CH-NON-00136, 05/2021